TY - JOUR
T1 - Osteopontin binds ICOSL promoting tumor metastasis
AU - RAINERI, DAVIDE
AU - Dianzani, C.
AU - CAPPELLANO, GIUSEPPE
AU - Maione, F.
AU - BALDANZI, GIANLUCA
AU - Iacobucci, I.
AU - Clemente, N.
AU - Baldone, G.
AU - Boggio, E.
AU - Gigliotti, C. L.
AU - BOLDORINI, Renzo Luciano
AU - Rojo, J. M.
AU - Monti, M.
AU - Birolo, L.
AU - DIANZANI, Umberto
AU - CHIOCCHETTI, Annalisa
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020
Y1 - 2020
N2 - ICOSL/ICOS are costimulatory molecules pertaining to immune checkpoints; their binding transduces signals having anti-tumor activity. Osteopontin (OPN) is here identified as a ligand for ICOSL. OPN binds a different domain from that used by ICOS, and the binding induces a conformational change in OPN, exposing domains that are relevant for its functions. Here we show that in vitro, ICOSL triggering by OPN induces cell migration, while inhibiting anchorage-independent cell growth. The mouse 4T1 breast cancer model confirms these data. In vivo, OPN-triggering of ICOSL increases angiogenesis and tumor metastatization. The findings shed new light on ICOSL function and indicate that another partner beside ICOS may be involved; they also provide a rationale for developing alternative therapeutic approaches targeting this molecular trio.
AB - ICOSL/ICOS are costimulatory molecules pertaining to immune checkpoints; their binding transduces signals having anti-tumor activity. Osteopontin (OPN) is here identified as a ligand for ICOSL. OPN binds a different domain from that used by ICOS, and the binding induces a conformational change in OPN, exposing domains that are relevant for its functions. Here we show that in vitro, ICOSL triggering by OPN induces cell migration, while inhibiting anchorage-independent cell growth. The mouse 4T1 breast cancer model confirms these data. In vivo, OPN-triggering of ICOSL increases angiogenesis and tumor metastatization. The findings shed new light on ICOSL function and indicate that another partner beside ICOS may be involved; they also provide a rationale for developing alternative therapeutic approaches targeting this molecular trio.
UR - https://iris.uniupo.it/handle/11579/117095
U2 - 10.1038/s42003-020-01333-1
DO - 10.1038/s42003-020-01333-1
M3 - Article
SN - 2399-3642
VL - 3
SP - 615
JO - Communications Biology
JF - Communications Biology
IS - 1
ER -